See more : Linc Limited (LINCPEN.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Acer Therapeutics Inc. (ACER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acer Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Macquarie Group Limited (MCQEF) Income Statement Analysis – Financial Results
- Daicel Corporation (DACHF) Income Statement Analysis – Financial Results
- Cathay Pacific Airways Limited (CPCAF) Income Statement Analysis – Financial Results
- TGB Banquets and Hotels Limited (TGBHOTELS.BO) Income Statement Analysis – Financial Results
- American Biltrite Inc. (ABLT) Income Statement Analysis – Financial Results
Acer Therapeutics Inc. (ACER)
About Acer Therapeutics Inc.
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | 249.57K | 816.24K | 2.90M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.04K | 687.51K | 2.54M |
| Gross Profit | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | -16.47K | 128.73K | 363.10K |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | -6.60% | 15.77% | 12.51% |
| Research & Development | 11.92M | 6.51M | 11.85M | 13.85M | 12.45M | 8.73M | 6.50M | 10.04M | 12.12M | 9.18M | 6.32M | 3.34M | 2.58M | 2.11M | 8.39M | 13.07M | 7.61M | 9.89M | 632.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 0.00 | 2.22M | 2.02M | 0.00 | 0.00 | 5.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 2.41M | 2.22M | 2.02M | 3.34M | 3.42M | 5.46M | 550.18K | 3.13M | 120.35K | 130.29K | 528.35K | 975.65K | 685.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.63K | 68.70K | 2.15K | 37.91K | 303.68K | 219.94K | 169.30K | 216.62K | 237.16K | 246.15K | 1.82M | 1.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 528.35K | 975.65K | 730.47K |
| Cost & Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 794.38K | 1.66M | 3.27M |
| Interest Income | 1.82K | 49.27 | 13.58K | 471.27K | 412.55K | 14.85K | 0.00 | 0.00 | 15.46K | 14.99K | 280.00 | 932.00 | 1.66K | 1.76K | 100.24K | 477.61K | 688.30K | 81.93K | 5.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 101.43K | 0.00 | 0.00 | 0.00 | 987.00 | 245.06K | 0.00 | 0.00 | 1.98K | 2.27M | 350.30K | 3.14K | 500.65K | 278.13K | 19.98K | 16.10K | 984.00 | 7.32M | 868.93K | 55.06K | 54.16K | 55.40K | 33.71K | 13.95K |
| Depreciation & Amortization | -198.47K | -54.76K | 96.20K | -8.21K | 27.74K | 4.00K | 238.13K | 351.40K | 387.78K | 335.60K | 303.68K | 210.25K | 168.84K | 214.85K | 234.33K | 232.96K | 1.82M | 7.25M | 1.02M | 1.48K | 12.95K | 15.40K | 19.41K | 19.13K |
| EBITDA | -24.55M | -15.88M | -22.73M | -28.34M | -21.25M | -13.95M | -6.70M | -2.57M | -14.66M | -11.53M | -8.83M | -5.76M | -4.80M | -7.32M | -11.77M | -18.10M | -13.23M | -4.95M | -2.74M | -201.83K | -113.49K | -531.89K | -827.39K | -551.31K |
| EBITDA Ratio | 0.00% | -1,270.09% | 0.00% | 0.00% | -4,929.34% | 5,656.94% | -195.37% | -459.26% | -1,152.81% | -910.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38,961.47% | -28,472.35% | 0.00% | 0.00% | -5,155.33% | -707.07% | -213.13% | -101.37% | -19.00% |
| Operating Income | -24.61M | -15.95M | -22.80M | -29.90M | -21.71M | -13.95M | -7.99M | -12.09M | -15.07M | -11.92M | -9.13M | -5.97M | -4.97M | -4.35M | -11.97M | -16.74M | -14.90M | -12.20M | -3.76M | -117.92K | -144.25K | -544.82K | -846.92K | -367.37K |
| Operating Income Ratio | 0.00% | -1,265.75% | 0.00% | 0.00% | -5,024.81% | 5,662.97% | -275.08% | -473.10% | -1,184.68% | -941.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -36,030.81% | -32,067.06% | 0.00% | 0.00% | -3,012.06% | -898.67% | -218.31% | -103.76% | -12.66% |
| Total Other Income/Expenses | -1.62M | 574.40K | -82.62K | -1.02M | 433.10K | -246.30K | -1.28M | 74.61K | 15.62K | -4.73M | 202.96K | -3.14K | -498.99K | 2.91M | 115.15K | 2.68M | 838.74K | -7.21M | -860.56K | 85.39K | -17.80K | 2.47K | -120.00 | 203.07K |
| Income Before Tax | -26.24M | -15.37M | -22.89M | -29.42M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -32.53K | -162.05K | -542.34K | -847.04K | -164.30K |
| Income Before Tax Ratio | 0.00% | -1,220.16% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -830.91% | -1,009.56% | -217.32% | -103.77% | -5.66% |
| Income Tax Expense | 1.62M | -645.31K | 11.81K | -537.75K | -432.12K | 246.30K | 1.04M | -4.74K | 4.13K | 2.31M | -202.96K | 5.97M | 5.47M | 1.43M | 11.85M | 14.67M | 14.06M | 19.41M | 4.62M | -30.33K | 54.91K | 52.93K | 33.83K | -189.12K |
| Net Income | -27.86M | -14.73M | -22.90M | -28.88M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -87.59K | -199.16K | -597.74K | -880.75K | -178.25K |
| Net Income Ratio | 0.00% | -1,168.94% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -2,237.24% | -1,240.76% | -239.51% | -107.90% | -6.14% |
| EPS | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
| EPS Diluted | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
| Weighted Avg Shares Out | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
| Weighted Avg Shares Out (Dil) | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing Higher
Acer Therapeutics (ACER) stock is on the rise Monday as investors speculate about a possible merger with Relief Therapeutics. The post ACER Stock: The Merger Rumor That Has Acer Therapeutics Racing Higher appeared first on InvestorPlace.
ACER Stock Price Increases Over 100% Pre-Market: What You Should Know About The Company
The stock price of Acer Therapeutics Inc (NASDAQ: ACER) has increased by over 100% pre-market as of 6:00 AM ET. This is what you should know about the company.a The post ACER Stock Price Increases Over 100% Pre-Market: What You...
Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
NEWTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results...
Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions
Targeting a pre-NDA meeting with FDA in Q2 2021 Targeting a pre-NDA meeting with FDA in Q2 2021
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders
Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021 Topline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021
Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results...
Acer unveils Intel GPU-toting laptops, revamped Chromebooks and an Alexa-killing smartspeaker
There’s something for everyone
Acer Unveils First Snapdragon 7c-Powered Chromebook
Spin 513 is not the only new Acer Chrome OS device.
Acer Drops Six New Predator & Nitro Gaming Monitors
A monitor for every type of gamer.
Source: https://incomestatements.info
Category: Stock Reports